Search

Your search keyword '"Twardowski, P."' showing total 13 results
Start Over Author "Twardowski, P." Publisher american society of clinical oncology
13 results on '"Twardowski, P."'

3. Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).

Author

Agarwal, Neeraj, Tangen, Catherine M., Hussain, Maha H.A., Gupta, Shilpa, Plets, Melissa, Lara, Primo N., Harzstark, Andrea L., Twardowski, Przemyslaw W., Paller, Channing J., Zylla, Dylan, Zibelman, Matthew R., Levine, Ellis, Roth, Bruce J., Goldkorn, Amir, Vaena, Daniel A., Kohli, Manish, Crispino, Tony, Vogelzang, Nicholas J., Thompson Jr, Ian M., and Quinn, David I.

Published
2022
Full Text
View/download PDF

4. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.

Author

Denmeade, Samuel R, Wang, Hao, Agarwal, Neeraj, Smith, David C, Schweizer, Michael T, Stein, Mark N, Assikis, Vasileios, Twardowski, Przemyslaw W, Flaig, Thomas W, Szmulewitz, Russell Z, Holzbeierlein, Jeffrey M, Hauke, Ralph J, Sonpavde, Guru, Garcia, Jorge A, Hussain, Arif, Sartor, Oliver, Mao, Shifeng, Cao, Harry, Fu, Wei, and Wang, Ting

Published
2021
Full Text
View/download PDF

5. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.

Author

Hussain, Maha, Daignault-Newton, Stephanie, Twardowski, Przemyslaw W., Albany, Costantine, Stein, Mark N., Kunju, Lakshmi P., Siddiqui, Javed, Wu, Yi-Mi, Robinson, Dan, Lonigro, Robert J., Cao, Xuhong, Tomlins, Scott A., Mehra, Rohit, Cooney, Kathleen A., Montgomery, Bruce, Antonarakis, Emmanuel S., Shevrin, Daniel H., Corn, Paul G., Whang, Young E., and Smith, David C.

Published
2018
Full Text
View/download PDF

6. Bone biomarkers and subsequent survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): Results from the phase III SWOG S1216 trial of androgen deprivation +/- orteronel.

Author

Lara, Primo N, Mayerson, Edward, Gertz, Erik, Tangen, Catherine, Goldkorn, Amir, Van Loan, Marta, Hussain, Maha H. A., Gupta, Shilpa, Zhang, Jingsong, Parikh, Mamta, Twardowski, Przemyslaw, Quinn, David I., LeBlanc, Michael Leo, Thompson, Ian M, and Agarwal, Neeraj

Published
2023
Full Text
View/download PDF

9. Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer.

Author

Goldkorn, Amir, Ely, Benjamin, Quinn, David I., Tangen, Catherine M., Fink, Louis M., Tong Xu, Twardowski, Przemyslaw, Van Veldhuizen, Peter J., Agarwal, Neeraj, Carducci, Michael A., Monk III, J. Paul, Datar, Ram H., Garzotto, Mark, Mack, Philip C., Lara Jr., Primo, Higano, Celestia S., Hussain, Maha, Thompson Jr., Ian Murchie, Cote, Richard J., and Vogelzang, Nicholas J.

Published
2014
Full Text
View/download PDF

12. Primary gonadal germ cell tumor associated with acute leukemia with common cytogenetics.

Author

Menon R, Twardowski P, Forman SJ, Huang Q, Slovak ML, and Krishnan A

Subjects
Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor analysis, Bone Marrow Transplantation, Cytogenetic Analysis, Humans, Lymphoma, Large-Cell, Anaplastic drug therapy, Lymphoma, Large-Cell, Anaplastic genetics, Male, Middle Aged, Neoplasms, Germ Cell and Embryonal drug therapy, Neoplasms, Germ Cell and Embryonal genetics, Prognosis, Testicular Neoplasms drug therapy, Testicular Neoplasms genetics, Lymphoma, Large-Cell, Anaplastic diagnosis, Neoplasms, Germ Cell and Embryonal diagnosis, Testicular Neoplasms diagnosis
Published
2010
Full Text
View/download PDF

13. Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy.

Author

Somlo G, Frankel P, Chow W, Leong L, Margolin K, Morgan R Jr, Shibata S, Chu P, Forman S, Lim D, Twardowski P, Weitzel J, Alvarnas J, Kogut N, Schriber J, Fermin E, Yen Y, Damon L, and Doroshow JH

Subjects
Adult, Breast Neoplasms pathology, California, Combined Modality Therapy, Disease-Free Survival, Female, Hematopoietic Stem Cell Transplantation, Humans, Medical Records, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Retrospective Studies, Survival Analysis, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms mortality, Breast Neoplasms therapy
Abstract

Purpose: To improve treatment outcome for patients presenting with inflammatory breast cancer (IBC), we have sequentially developed and tested single and tandem dose-intense chemotherapy regimens (DICT). Tumor- and treatment-related factors were analyzed to generate a prognostic model., Patients and Methods: Between May 1989 and April 2002, 120 patients received conventional-dose chemotherapy, surgery, and sequentially developed single- or tandem-cycle DICT. Disease- and treatment-specific features were subjected to univariate and multivariate analysis to correlate with outcome., Results: At a median follow-up of 61 months (range, 21 to 161 months), estimated 5-year relapse-free survival (RFS) and overall survival (OS) were 44% (95% CI, 34% to 53%) and 64% (95% CI, 55% to 73%), respectively. In an age-adjusted multivariate analysis, RFS was better in patients with estrogen receptor (ER)/progesterone receptor (PR)-positive tumors (P =.002), for patients with fewer than four involved axillary nodes before DICT (P =.01), and in patients treated with radiation therapy (P =.001) and tandem DICT (P =.049). OS was improved in patients with ER/PR-positive tumors (P =.002), in those with fewer than four involved axillary nodes before DICT (P =.03), and in patients treated with radiation therapy (P =.002)., Conclusion: This retrospective analysis suggests that either single or tandem DICT can be administered safely and may benefit selected patients with stage IIIB IBC. Those with receptor-negative IBC and with four or more involved axillary nodes before DICT need improved neoadjuvant and postadjuvant intensification therapy. A prospective randomized trial of single versus tandem DICT would be required to confirm the potential benefit of tandem DICT in the setting of IBC.

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results